Microneedle patch and administration control method

Through the multi-layer structural design of microneedle patches, the use of resistance detection and electric heating layer to control drug release has solved the problem of inaccurate drug release in the existing dry eye syndrome treatment, personalized treatment has been achieved, and the accuracy of treatment has been improved Sex and safety.

CN119055944APending Publication Date: 2024-12-03EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV

Patent Information

Application Number
CN202411344749.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-25
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The existing treatment methods for dry eye syndrome have problems such as inaccurate drug release, short action time, and may irritate biological tissue on the surface of the eye, making it difficult to personalize the treatment for inflammatory responses.

Method used

Design a microneedle patch, adopting a multi-layer structure, including the base film of the patch, a microcontrol layer, an intermediate connecting layer and a microneedle array layer, and use a resistance detection layer and an electrical heating layer to control drug release, combining thermal phase change materials and IL-17RA receptor, enabling temporal and spatial dosing control.

Benefits of technology

The accuracy and flexibility of drug release are achieved, and personalized treatment is carried out according to changes in inflammatory factors, which improves the accuracy and safety of treatment and avoids the risk of overdose irritating the eye surface.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055944A_ABST
    Figure CN119055944A_ABST
Patent Text Reader

Abstract

The invention provides a micro-needle patch. The micro-needle patch sequentially comprises a patch base film, a micro-control layer, a middle connecting layer and a micro-needle array layer from top to bottom, the microneedle array layer comprises a plurality of microneedles, and each microneedle is of a hollow structure penetrating through the tip end from the bottom end; a thermal phase change material for mixing medicine is arranged in the hollow structure; electric heating layers are arranged on the inner wall of the hollow structure and the bottom end of the needle body; a resistance detection layer is arranged on the outer wall of the hollow structure, and an interleukin receptor IL-17RA is coupled to the resistance detection layer; the middle connecting layer comprises a plurality of first connecting circuits and a plurality of second connecting circuits; each first connecting circuit is electrically connected with the resistance detection layer of at least one microneedle, each second connecting circuit is electrically connected with the electric heating layer of at least one microneedle, and the first circuit and the second circuit are respectively connected to the micro-control layer; and the micro-control layer detects the resistance change of the resistance detection layer on the micro-needle based on the first connection circuit, and performs heating control on the electric heating layer of at least one micro-needle based on the resistance change and the second connection circuit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of intelligent medical technology, and in particular to a microneedle patch and drug delivery control technology. Background Art

[0002] Dry Eye Syndrome (DES) is a common eye disease with far-reaching and complex impacts. It is a common eye disease with the ocular surface inflammatory microenvironment as the core pathogenic factor, involving insufficient tear secretion, reduced tear quality, tear dynamics and overall homeostasis disorders caused by inflammation. The conjunctiva, as an important protective barrier of the eyeball, has a delicate structure and diverse functions. It consists of three parts: the palpebral conjunctiva, the bulbar conjunctiva and the fornix conjunctiva, which together maintain the moisture and cleanliness of the eyeball. The cornea of ​​a normal person is covered with a thin film formed by tears. The upper and lower eyelid conjunctiva are in direct contact with the cornea during each blink. The bulbar conjunctiva is covered on the surface of the white sclera and together with the fornix conjunctiva, it forms an important part of the local environment of the ocular surface. When dry eye syndrome occurs, the microenvironment homeostasis of the conjunctiva is directly affected by inflammation, resulting in impaired function, aggravating the occurrence and development of the disease and exacerbating eye discomfort.

[0003] In the pathological process of dry eye syndrome, the activation of IL-17A, a representative key inflammatory site, triggers an inflammatory cascade reaction and causes an inflammatory factor storm. Under the influence of the inflammatory microenvironment, the conjunctiva often shows changes such as congestion, edema, and roughness. These changes not only affect the patient's visual quality, but may also cause a series of secondary eye diseases. For example, long-term dry eyes may cause damage to conjunctival epithelial cells, leading to chronic conjunctivitis, keratitis, etc. These diseases will further aggravate the symptoms of dry eyes, forming a vicious circle.

[0004] In order to effectively treat dry eye syndrome and protect the health of the conjunctiva, comprehensive treatment measures are often taken clinically. First of all, artificial tears can be used to supplement the problem of insufficient tear secretion to relieve eye dryness and discomfort. At the same time, physical therapies such as hot compresses and massage can promote eye blood circulation and tear secretion, and improve tear film stability.

[0005] In addition, for conjunctival lesions, we can use anti-inflammatory, anti-allergic and other eye drops for treatment to relieve conjunctival inflammation and congestion symptoms. For conjunctival epithelial cell damage caused by dry eyes, we can also consider using drugs that promote cell repair and regeneration to accelerate the recovery of conjunctival tissue.

[0006] Ocular surface drug release is the first choice for dry eye disease. Targeted intervention at key inflammatory response sites is an accurate and efficient treatment strategy. In the current market, ocular surface drug release is mainly achieved through eye drops and ointments. However, these methods often have obvious shortcomings such as transient loss, short duration of action, rapid increase in drug concentration in the ocular surface microenvironment in a short period of time, missing the peak of disease progression at the intervention time point, and lack of targeted treatment for local severe lesions on the ocular surface. If high-frequency eye drops are used, excessive drug concentration may stimulate ocular surface biological tissues and even cause drug toxicity damage. Summary of the invention

[0007] The present application proposes a microneedle patch, which is combined with a microneedle array with detection function to achieve drug administration control in time and space.

[0008] The present application provides a microneedle patch, the area of ​​the microneedle patch is 4-5 square centimeters, which is adapted to the size of a conventional eyelid conjunctiva. The microneedle patch is a multi-layer structure, which is sequentially laminated from top to bottom and includes: a patch base film, a micro-control layer, an intermediate connection layer, and a microneedle array layer; the microneedle array layer includes a plurality of microneedles, each of which is a hollow structure extending from the bottom end of the needle body to the tip of the needle body; a thermal phase change material with a mixed drug is arranged in the hollow structure; an electric heating layer is arranged on the inner wall of the hollow structure and the bottom end of the needle body, the electric heating layer covers the thermal phase change material and leaves a gap for releasing the drug near the tip of the needle body; A resistance detection layer extending to the bottom end of the needle body is provided on the outer wall of the hollow structure, and the resistance detection layer is coupled to the interleukin receptor IL-17RA; the intermediate connection layer includes a plurality of first connection circuits and a plurality of second connection circuits; each of the first connection circuits is electrically connected to the resistance detection layer of at least one microneedle, and each of the second connection circuits is electrically connected to the electric heating layer of at least one microneedle, and the first circuit and the second circuit are respectively connected to the micro-control layer; the micro-control layer detects the resistance change of the resistance detection layer on the corresponding microneedle based on the first connection circuit, and controls the heating of the electric heating layer of at least one microneedle based on the resistance change and the second connection circuit.

[0009] Optionally, the drug component is bimegetinib, and the thermal phase change conductive material undergoes a solid-liquid phase change when heated, and liquid drug molecules flow out from the bottom of the needle body to act on the conjunctiva.

[0010] Optionally, the microneedle array layer is divided into multiple areas, and the resistance detection layers of multiple microneedles in each area are connected in series and electrically connected to an independent first connection circuit; the electric heating layers of multiple microneedles in each area are connected in series and electrically connected to an independent second connection circuit; when the resistance of any microneedle in the area increases, the micro-control layer electrically heats the electric heating layer of the microneedles in the area by electrically connecting the second connection circuit of the area.

[0011] Optionally, the resistance detection layer of each microneedle in the microneedle array layer is electrically connected to an independent first connection circuit; the electric heating layer of each microneedle is electrically connected to an independent second connection circuit; when the resistance of any microneedle increases, the micro-control layer electrically heats the electric heating layer of the microneedle by electrically connecting the second connection circuit of the microneedle.

[0012] Optionally, the resistance detection layer is a conductive path formed by a conductive layer coupled with an interleukin receptor IL-17RA, the conductive path extends from the tip of the needle body to the bottom of the needle body, and is electrically connected to the first connection circuit at the bottom of the needle body; When the inflammatory factor IL-17A interacts with IL-17RA, reactants are produced that increase the resistance of the conductive pathway and are recognized by the micro-control layer.

[0013] Optionally, the electric heating layer extends along the inner wall of the hollow structure from the tip of the needle body to the bottom end of the needle body.

[0014] Optionally, the microneedle patch is of a configuration that matches the shape of the conjunctiva, and the patch base membrane is made of a hydrophilic and breathable material; each of the microneedles is made of a conductive insulating material.

[0015] Optionally, the micro-control layer includes: a micro-control chip and a power supply, and the power supply is electrically connected to each first connection circuit and each second connection circuit respectively through the micro-control chip.

[0016] Optionally, the heating temperature of the electric heating layer of the microneedle is 38 to 42 degrees Celsius; The micro-control layer is activated once at a first predetermined time interval, and the heating temperature is determined according to the time to heat the entire electric heating layer to a predetermined temperature to control the release rate of the drug; The micro-control layer is activated once at a second predetermined time interval, and the heating temperature of the conductive heating wire in each microneedle is differentially set according to the difference between the resistance of each microneedle and the preset reference resistance to control the release rate of the drug molecules of the thermal phase change material.

[0017] According to another aspect of the present application, the present application also provides a drug administration control method based on the microneedle patch, the method comprising: The micro-control layer is activated at intervals of a first time length to heat the electric heating layer, and the heating temperature is determined based on preset time-temperature relationship information; The micro-control layer is activated at a first time interval to obtain resistance information of each microneedle of the microneedle array layer, and based on preset resistance-temperature relationship information, the electric heating layer in the microneedle is subjected to differential heating control; After the electric heating layer is heated, the thermal phase change material in contact with the electric heating layer undergoes a solid-liquid phase change, and the liquid drug molecules flow out of the hollow microneedles and act on the conjunctiva.

[0018] The design of the microneedle patch of the present application realizes the accuracy and flexibility of drug administration control. Through the control of the electric heating layer on the microneedle by the micro-control layer, the release rate of the drug molecules can be accurately controlled according to the preset time-temperature relationship information, thereby ensuring the effective distribution of the drug in time and space. At the same time, the micro-control layer can also realize differentiated heating control based on the resistance change caused by inflammatory factors, which means that the microneedle patch can be personalized for the degree of inflammation in different areas of the patient's body. In summary, the technical solution of the present application can realize drug administration in time and space for the conjunctiva. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 Schematic diagram of the structure of the microneedle patch provided in the embodiment of the present application Figure 2 and Figure 3 A schematic diagram of the structure of a microneedle array layer provided in an embodiment of the present application; Figure 4 A schematic diagram of the structure of the microneedle provided in the embodiment of the present application. DETAILED DESCRIPTION

[0020] In order to make the purpose, technical solution and advantages of the embodiments of the present application clearer, the technical solution in the embodiments of the present application will be clearly and completely described below in conjunction with the drawings in the embodiments of the present application. Obviously, the described embodiments are part of the embodiments of the present application, not all of the embodiments. Based on the embodiments in the present application, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of this application.

[0021] like Figures 1 to 4As shown, the present application introduces an innovative microneedle patch, which is a multi-layer structure, which is laminated in sequence from top to bottom and includes: a patch base film 1, a micro-control layer 2, an intermediate connection layer 3 and a microneedle array layer 4; the microneedle array layer 4 includes a plurality of microneedles 41, each of which is a hollow structure extending from the bottom end of the needle body to the tip of the needle body; a resistance detection layer 43 extending to the bottom end of the needle body is arranged on the outer wall of the hollow structure, and the interleukin receptor IL-17RA is coupled to the resistance detection layer 43; a thermal phase change material 5 of a mixed drug is arranged in the hollow structure; the inner wall of the hollow structure An electric heating layer is arranged on the wall and at the bottom end of the needle body, and the electric heating layer contacts the thermal phase change material 5; the intermediate connection layer 3 includes a plurality of first connection circuits and a plurality of second connection circuits; each of the first connection circuits is electrically connected to the resistance detection layer 43 of at least one microneedle, and each of the second connection circuits is electrically connected to the electric heating layer of at least one microneedle, and the first circuit and the second circuit are respectively connected to the micro-control layer 2; the micro-control layer 2 detects the resistance change of the resistance detection layer 43 on the corresponding microneedle based on the first connection circuit, and controls the heating of the electric heating layer of at least one microneedle based on the resistance change and the second connection circuit.

[0022] Specifically, the area of ​​the microneedle patch is 4-5 square centimeters, and the length of the microneedle is 0.83mm-1mm; this microneedle patch is designed to perfectly fit the size of the regular eyelid conjunctiva, ensuring that it can cover the entire area that needs treatment when used. The microneedle patch adopts a multi-layer structure design, and these layers are closely fitted from top to bottom to form a complex system.

[0023] First, the patch base film 1 is the bottom layer of the microneedle patch, which provides a solid foundation for the entire structure. Next is the micro-control layer 2, which is responsible for controlling the operation of the entire microneedle patch. Above the micro-control layer 2 is the intermediate connection layer 3, which consists of multiple first connection circuits and multiple second connection circuits. The function of these circuits is to connect the micro-control layer 2 with the microneedle array layer 4 to ensure the transmission of signals and energy.

[0024] The microneedle array layer 4 is located above the intermediate connection layer 3 and is the core part of the microneedle patch. This layer includes a plurality of microneedles 41, each of which is a hollow structure that runs from the bottom of the needle body to the tip of the needle body. A resistance detection layer 43 is provided on the outer wall of these hollow structures, to which the interleukin receptor IL-17RA is coupled. In this way, the microneedle patch can monitor and detect the inflammatory response on the eyelid conjunctiva in real time.

[0025] Inside the hollow structure of each microneedle, a thermal phase change material 5 mixed with drugs is also provided. This material can undergo phase change at a specific temperature, thereby releasing the drug. In order to control this phase change process, an electric heating layer is also provided on the inner wall of the hollow structure of each microneedle. This heating layer can accurately control the temperature of the thermal phase change material 5 by electric heating, thereby achieving accurate release of the drug. Specifically, the thermal phase change material 5 is a hydrogel or other biomaterial that can be decomposed under heat.

[0026] The micro-control layer 2 detects the resistance change of the resistance detection layer 43 on the corresponding microneedle based on the first connection circuit. Through the resistance change, the micro-control layer 2 can monitor the inflammatory response of the eyelid conjunctiva in real time. Based on the resistance change and the second connection circuit, the micro-control layer 2 can also control the heating of the electric heating layer of at least one microneedle. In this way, the microneedle patch can accurately control the release time and dosage of the drug according to the inflammatory response of the eyelid conjunctiva, thereby achieving a more accurate and effective treatment effect.

[0027] Optionally, the composition of the drug is that the thermal phase change conductive material undergoes a solid-liquid phase change when heated, and the liquid drug molecules flow out from the bottom end of the needle body to act on the conjunctiva.

[0028] Specifically, the ingredients of the drug include Bimekizumab, a highly selective monoclonal IgG1 antibody that specifically inhibits interleukin 17A. In multiple clinical trials, Bimekizumab has shown significant efficacy. Specifically, this drug specifically binds to the target of interleukin 17A, effectively blocking its biological activity, thereby reducing the inflammatory response and improving the symptoms of related diseases.

[0029] On the other hand, the thermal phase-change conductive material undergoes a solid-liquid phase change when heated. This physical property causes the material to change from solid to liquid when the temperature rises, allowing liquid drug molecules to flow out from the bottom of the needle body. These drug molecules then act on the conjunctiva, the transparent mucous membrane on the surface of the eye, to exert their therapeutic effects. In this way, the drug can reach the lesion more directly and effectively, improving the treatment effect.

[0030] The method of mixing the drug component with the thermal phase change conductive material can be achieved by the following technical means: Microencapsulation technology: First, the drug ingredients are dissolved or dispersed in an appropriate solvent, and then the solution or dispersion is encapsulated in microcapsules of thermal phase change conductive materials by spray drying or phase separation technology. The shell of the microcapsule can be composed of biodegradable polymers such as polylactic acid and polycaprolactone to ensure that the drug can be released slowly.

[0031] Co-extrusion method: After mixing the drug component with the thermal phase change conductive material, the drug component is extruded through a twin-screw extruder. During the extrusion process, the drug component is evenly dispersed in the thermal phase change conductive material to form a composite material. This method is suitable for drug components with good thermal stability.

[0032] Solvent evaporation method: The drug component is dissolved in an organic solvent, and then the solution is mixed with a suspension of a thermal phase change conductive material. The solvent is evaporated by stirring, and the drug component is gradually deposited on the surface of the thermal phase change conductive material to form a wrapping structure.

[0033] In-situ polymerization method: Introduce monomers on the surface or inside of the thermal phase change conductive material, generate polymers through in-situ polymerization, and then wrap the drug ingredients in the polymer. This method can achieve a close combination of drug ingredients and thermal phase change conductive materials.

[0034] Self-assembly technology: Utilizing the specific chemical properties of the surface of thermal phase-change conductive materials, drug molecules are self-assembled to form an ordered monolayer or multilayer structure on the surface of the material. This method is suitable for drug ingredients with smaller molecular weight.

[0035] Through the above method, the drug components can be effectively combined with the thermal phase change conductive material to achieve controlled and targeted release of the drug, thereby improving the efficacy and safety of the drug. In addition, the thermal phase change conductive material can generate heat under the change of body temperature, which helps the local release of the drug and further enhances the therapeutic effect.

[0036] Specifically, in addition to encapsulation and mixing, the combination of drug components and thermal phase change conductive materials can also adopt an embedding or stacking strategy. The embedding method is to embed the drug components directly into the matrix of the thermal phase change conductive material to form a composite material similar to a mosaic structure. This strategy can ensure that the drug components are evenly distributed inside the material, while using the characteristics of the thermal phase change conductive material to regulate the release rate of the drug.

[0037] The stacking strategy is to stack the drug ingredients and thermal phase change conductive materials layer by layer to form a multi-layer structure. This structure can use the interaction and phase change process between the layers to achieve precise control of drug release. For example, a drug layer can be sandwiched between the thermal phase change conductive material layers. When the material undergoes a phase change, it will drive the drug layer to gradually release the drug ingredients.

[0038] Specifically, the thermal phase change material layer includes a polydimethylsiloxane (PDMS) substrate and a hydrogel, drug molecules are mixed in the hydrogel, and there are one or more microcavities in the PDMS substrate, with a diameter size ranging from 100 to 200 μm. Specifically, a droplet template method can be used to form a microcavity with an opening, such as using a surface tension liquid such as water or glycerol to produce a spherical microcavity, and the drug-loaded hydrogel releases the drug through one or more narrow openings of multiple microcavities. During the manufacturing process, PDMS and the drug-loaded hydrogel are polymerized simultaneously to ensure that the hydrogel matrix is ​​embedded in the microcavity during the curing process. The drug-loaded hydrogel matrix is ​​initially in a dehydrated state and expands when in contact with an aqueous environment to facilitate drug delivery. The hydrogel accelerates the release of drug molecules when heated.

[0039] In one embodiment, the hydrogel monomers include, but are not limited to, hydroxyethyl methacrylate (HEMA), methacrylic acid (MAA), N-vinyl pyrrolidone (NVP), ethylene glycol dimethacrylate (EGDMA), gelatin, alginate, cellulose, and the like.

[0040] Optionally, the microneedle array layer 4 is divided into multiple regions, and the resistance detection layer 43 of multiple microneedles 41 in each region is connected in series and electrically connected to an independent first connection circuit; the electric heating layer of multiple microneedles 41 in each region is connected in series and electrically connected to an independent second connection circuit; when the resistance of any microneedle in the region increases, the micro-control layer 2 electrically heats the electric heating layer of the microneedles in the region by electrically connecting the second connection circuit of the region. Specifically, when the resistance value of any microneedle in a certain region increases abnormally, the micro-control layer 2 in the microneedle array layer 4 will detect this change. Subsequently, the micro-control layer 2 will electrically heat the electric heating layer of the microneedles in the entire region by electrically connecting to the second connection circuit of the region. This heating operation can quickly restore the resistance value of the microneedles and ensure the normal operation of the microneedle array layer 4. In this way, the microneedle array layer 4 can not only realize real-time monitoring of the resistance, but also quickly take heating measures when the resistance is abnormal, thereby improving the stability and reliability of the entire system.

[0041] Optionally, the resistance detection layer 43 of each microneedle of the microneedle array layer 4 is electrically connected to an independent first connection circuit; the electric heating layer of each microneedle is electrically connected to an independent second connection circuit; when the resistance of any microneedle increases, the micro-control layer 2 electrically heats the electric heating layer of the microneedle through the second connection circuit electrically connected to the microneedle. Each microneedle is equipped with an independent resistance detection layer 43 connected to the first connection circuit, and such a configuration enables the resistance change of each microneedle to be accurately captured. At the same time, each microneedle is also independently connected to a second connection circuit, which is specifically responsible for powering its electric heating layer. Once the resistance value of a microneedle rises, the micro-control layer 2 will respond quickly, and the electric heating layer of the microneedle will be energized through the corresponding second connection circuit for local heating treatment. Such a design not only improves the response speed of the system, but also ensures that each microneedle can be controlled in a timely and accurate manner, thereby greatly enhancing the flexibility and efficiency of the microneedle array.

[0042] In addition, in order to further optimize the performance of the microneedle array layer 4, the micro-control layer 2 also has a temperature monitoring function. A temperature sensor is arranged next to the microneedle electric heating layer in each area, and these sensors are electrically connected to the micro-control layer 2. When the micro-control layer 2 energizes and heats the electric heating layer in a certain area, the temperature sensor monitors the temperature change of the area in real time. The micro-control layer 2 dynamically adjusts the intensity and time of the energized heating according to the data provided by the temperature sensor to ensure that the microneedle array layer 4 works within the optimal temperature range.

[0043] In order to improve the response speed and accuracy of the system, the micro-control layer 2 also integrates an intelligent algorithm. The algorithm can predict possible problems of the microneedle array layer 4 based on the resistance value and temperature data, and make adjustments in advance. For example, when the resistance value begins to rise slightly, the algorithm will determine whether heating is needed in advance to avoid malfunctions caused by further increase in resistance value. In addition, the intelligent algorithm can also automatically adjust the working parameters of the microneedles according to the frequency of use and environmental conditions of the microneedle array layer 4 to adapt to different application scenarios.

[0044] In order to ensure the stability of the microneedle array layer 4 during long-term operation, the micro-control layer 2 also has a self-diagnosis function. When the system starts, the micro-control layer 2 will conduct a comprehensive test on the entire microneedle array layer 4 to ensure that the resistance value and temperature sensor of each microneedle are in normal working condition. During operation, the micro-control layer 2 will perform self-diagnosis regularly to detect and deal with potential problems in a timely manner. If a microneedle is found to be faulty, the micro-control layer 2 will automatically isolate it from the array and replace it with a spare microneedle to ensure the continuous operation of the entire system.

[0045] In summary, through the integration of resistance detection, temperature monitoring, intelligent algorithms and self-diagnosis functions, the microneedle array layer 4 can not only achieve real-time monitoring and rapid response to the microneedle status, but also improve the stability and reliability of the system. This comprehensive microneedle array layer 4 design provides a solid foundation for the application of microneedle technology in medical and bioengineering fields.

[0046] Optionally, the resistance detection layer 43 is a conductive path formed by a conductive layer coupled with the interleukin receptor IL-17RA, the conductive path extends from the needle tip to the needle bottom, and is electrically connected to the first connection circuit at the needle bottom; When the inflammatory factor IL-17A interacts with IL-17RA, reactants are produced, which increase the resistance of the conductive path and are recognized by the micro-control layer 2. In an optional embodiment, the resistance detection layer 43 can be a conductive layer coupled with the interleukin receptor IL-17RA, which can form a conductive path. This conductive path extends from the tip of the needle body and extends all the way to the bottom of the needle body. At the bottom of the needle body, this conductive path is electrically connected to the first connection circuit. When the inflammatory factor IL-17A interacts with the IL-17RA receptor, specific reactants are produced, which cause the resistance value of the conductive path to increase. This change in resistance value can be accurately identified and detected by the micro-control layer 2.

[0047] IL-17A is a cytokine that plays an important role in immune response. When the body is infected or damaged, IL-17A can be produced by inflammatory cells and released into the surrounding environment, triggering an inflammatory response. The inflammatory factor receptor is IL-17RA, a protein located on the cell surface that can specifically bind to IL-17A, thereby transmitting inflammatory signals into the cell and triggering an inflammatory response in the cell. In this way, IL-17A and its receptors play a vital role in regulating immune responses and inflammatory processes.

[0048] In order to ensure the accuracy of the detection, the micro-control layer 2 includes a microprocessor and an analog-to-digital converter. The microprocessor is responsible for processing the resistance change signal transmitted from the conductive path and converting it into a digital signal. The analog-to-digital converter converts the analog signal into a digital signal so that the microprocessor can perform further analysis and processing.

[0049] At the bottom of the needle, a wireless transmission module is also set up. This module can send the data processed by the microprocessor to external devices such as smartphones, tablets or dedicated monitoring devices through wireless signals. In this way, users can monitor the concentration changes of inflammatory factors in real time and take corresponding treatment measures in time.

[0050] In order to improve the sensitivity and accuracy of detection, the conductive layer uses a special nanomaterial. This material has excellent conductivity and good biocompatibility, and can ensure the sensitivity and stability of resistance changes under the action of inflammatory factors. In addition, the high specific surface area of ​​the nanomaterial also helps to improve the binding efficiency with the IL-17RA receptor, thereby enhancing the sensitivity of detection.

[0051] In practical applications, the needle body can be designed as a disposable microneedle to avoid cross infection. The size of the microneedle is very small, which can achieve painless puncture, allowing the patient to complete the test without knowing it. The material selection of the needle body can be biodegradable material, which can be naturally degraded after use to reduce environmental pollution.

[0052] In order to further improve the convenience of detection, the system can also be equipped with a dedicated application. The application can receive the data sent by the wireless transmission module and display the test results in the form of charts or numerical values ​​on the user interface. The application can also provide personalized health advice and early warning prompts based on the test data to help users better manage their health conditions.

[0053] In summary, by combining the resistance detection layer 43, the micro-control layer 2, the wireless transmission module and the application, we have built an efficient, convenient and intelligent inflammation detection system. This system can not only monitor the concentration changes of inflammatory factors in real time, but also provide users with accurate health advice, and has broad application prospects.

[0054] Optionally, the electric heating layer extends along the inner wall of the hollow structure from the tip of the needle body to the bottom end of the needle body.

[0055] Optionally, the electric heating layer is arranged along the inner wall of the hollow structure, starting from the tip of the needle body and extending to and covering the bottom of the needle body. This arrangement ensures that the electric heating layer can heat the inside of the hollow structure evenly and effectively, and both the tip and the bottom of the needle body can obtain sufficient heat transfer. In addition, the continuous extension of the electric heating layer along the inner wall of the hollow structure also enhances the overall stability and durability of the structure. It reduces the material stress concentration caused by temperature changes and avoids possible structural failure. At the same time, this design also simplifies the construction and maintenance of the heating system, reduces the cost of use, and improves the reliability and service life of the equipment.

[0056] Optionally, the microneedle patch is of a configuration that matches the shape of the conjunctiva, and the patch base film 1 is made of a hydrophilic and breathable material; each of the microneedles is made of a conductive insulating material.

[0057] In an optional embodiment, the microneedle patch has a specific configuration that matches the shape of the conjunctiva. This configuration ensures that the patch can fit closely on the surface of the conjunctiva, thereby improving the efficiency and accuracy of drug delivery. In order to further improve the wearing comfort and breathability, the basement membrane of the patch adopts a hydrophilic and breathable material. This material can not only keep the surface of the patch moist, but also ensure the circulation of air, reducing the discomfort when wearing.

[0058] In addition, each of the microneedles is made of a conductive insulating material. This material is selected to ensure that the microneedles can effectively guide the current when delivering drugs, while avoiding unnecessary stimulation or damage caused by the current passing through the eye tissue. The use of conductive insulating materials not only improves the safety of the microneedle patch, but also ensures precise control during drug delivery. Through this carefully designed microneedle patch, efficient, safe and comfortable drug delivery can be achieved, which is particularly suitable for ocular drug treatment.

[0059] Optionally, the micro-control layer 2 includes: a micro-control chip and a power supply, and the power supply is electrically connected to each first connection circuit and each second connection circuit respectively through the micro-control chip.

[0060] Optionally, the heating temperature of the electric heating layer of the microneedle is 38 to 42 degrees Celsius; it will not harm the patient's eyes.

[0061] The micro-control layer 2 is started once at a first predetermined time interval, and the heating temperature is determined according to the time to heat the entire electric heating layer to a predetermined temperature to control the release rate of the drug; The micro-control layer 2 is activated once at a second predetermined time interval, and the heating temperature of the conductive heating wire in each microneedle is differentially set according to the difference between the resistance of each microneedle and the preset reference resistance to control the release rate of the drug molecules of the thermal phase change material 5.

[0062] During the operation of the micro-control layer 2, it will strictly follow the set program and automatically start once every pre-set first time period. At each start-up, the micro-control layer 2 will accurately calculate and set a suitable heating temperature based on the current time information. This temperature setting is to ensure that the entire electric heating layer can be evenly heated to a pre-set target temperature. In this way, the release rate of the drug can be effectively controlled so that it proceeds according to the expected plan, thereby achieving the best therapeutic effect.

[0063] In addition, the micro-control layer 2 will be started again every second pre-set time period. At each startup, the micro-control layer 2 will perform more detailed detection and adjustment. It will measure the resistance value of each microneedle and compare it with a pre-set reference resistance value. By analyzing the difference between the resistance value of each microneedle and the reference resistance value, the micro-control layer 2 can accurately calculate the heating temperature required for the conductive heating wire in each microneedle. This differentiated temperature setting enables the thermal phase change material 5 in each microneedle to release drug molecules at different rates, thereby achieving fine control of the drug release process. In this way, it can be ensured that the release of drug molecules is more in line with the needs of individualized treatment, improving the accuracy and effectiveness of treatment.

[0064] Optionally, the microcontroller chip has an intelligent control function, and can automatically adjust the heating power and time of the electric heating layer according to the resistance change data fed back by the resistance detection layer 43, so as to achieve precise control of the rate and amount of drug release.

[0065] Optionally, the microneedle patch further includes a temperature sensor, which is electrically connected to the micro-control layer 2 and is used to monitor the temperature of the microneedle array layer 4 in real time to ensure that the drug is released within an optimal temperature range while avoiding thermal damage to the conjunctival tissue.

[0066] Optionally, the microneedle array layer 4 of the microneedle patch is designed with adjustable microneedle length to adapt to conjunctival tissues of different thicknesses, ensuring that the drug can accurately act on the target area.

[0067] Optionally, the microneedle patch further comprises a flexible circuit board, which is electrically connected to the intermediate connecting layer 3 to provide better fit and flexibility, thereby ensuring the stability and comfort of the microneedle patch on the conjunctiva.

[0068] Optionally, the microneedle patch further includes a biocompatible protective layer, which covers the surface of the microneedle array layer 4 and is used to protect the microneedles from contamination before the patch is used, and gradually dissolves after the patch is used to ensure that the drug can be released smoothly.

[0069] Optionally, the microneedle patch also includes a wireless communication module, which is electrically connected to the micro-control layer 2 and is used to transmit real-time data of the microneedle patch to an external device, such as a smart phone or a medical monitoring system, so that doctors or patients can monitor the drug release status and conjunctival health in real time.

[0070] Optionally, the microneedle patch also includes a detachable shading layer, which covers the surface of the microneedle patch and is used to prevent the influence of light on the stability of the drug during the use of the patch. At the same time, the shading layer is easy to remove after use to observe the use of the patch and the reaction of the conjunctiva.

[0071] According to another aspect of the present application, the present application also provides a drug administration control method based on the microneedle patch, the method comprising: The micro-control layer 2 is started to heat the electric heating layer at intervals of a first time, and the heating temperature is determined based on preset time-temperature relationship information; The micro-control layer 2 is started at a first time interval to obtain the resistance information of each microneedle of the microneedle array layer 4, and the electric heating layer in the microneedle is subjected to differential heating control based on the preset resistance-temperature relationship information; After the electric heating layer is heated, the thermal phase change material 5 in contact with the electric heating layer undergoes a solid-liquid phase change, and the liquid drug molecules flow out of the hollow microneedles to act on the conjunctiva.

[0072] The drug administration control method further comprises the following steps: Before starting the micro-control layer 2 to heat the electric heating layer, first check whether the micro-needle patch is correctly attached to the target area. If not, the micro-control layer 2 sends a prompt signal to remind the user to re-attach the micro-needle patch to ensure the accuracy and safety of drug delivery.

[0073] After the microneedle patch is correctly attached, the micro-control layer 2 will control the electric heating layer to perform intermittent heating within the first time period according to the preset time-temperature relationship information. In this way, it is possible to effectively avoid discomfort or damage to the skin tissue due to continuous high temperature.

[0074] During each heating process, the micro-control layer 2 monitors the resistance information of each microneedle in real time. Since the resistance of different microneedles may vary due to manufacturing differences, number of uses or environmental factors, the micro-control layer 2 will perform differentiated heating control on the electric heating layer of each microneedle based on the preset resistance-temperature relationship information. This ensures that each microneedle works at the same temperature, thereby achieving a uniform and consistent drug release effect.

[0075] After the electric heating layer is heated, the thermal phase change material 5 in contact with the electric heating layer undergoes a solid-liquid phase change, and the liquid drug molecules flow out of the hollow microneedles. In order to ensure that the drug can effectively act on the conjunctiva, the micro-control layer 2 will control the drug release time of the microneedle array layer 4 according to the preset drug release rate information. In this way, the drug's action time on the conjunctiva can be accurately controlled, thereby improving the drug's efficacy.

[0076] In addition, the micro-control layer 2 also has a real-time monitoring function and can detect the physiological parameters of the conjunctiva, such as temperature, humidity, etc. According to the changes in these parameters, the micro-control layer 2 can dynamically adjust the rate and amount of drug release to adapt to the physiological needs of different individuals, further improving the efficacy and safety of the drug.

[0077] In summary, the drug delivery control method based on the microneedle patch provided in the present application realizes differentiated heating control of the microneedle array layer 4 by precisely controlling the heating time and temperature of the electric heating layer, thereby ensuring uniform release of the drug, and dynamically adjusts the drug release strategy in combination with the real-time monitoring function, thereby achieving efficient and safe drug delivery effects.

[0078] It is obvious to those skilled in the art that the present application is not limited to the details of the above exemplary embodiments, and that the present application can be implemented in other specific forms without departing from the spirit or basic features of the present application. Therefore, from any point of view, the embodiments should be regarded as exemplary and non-restrictive, and the scope of the present application is defined by the attached claims rather than the above description, and it is intended that all changes falling within the meaning and scope of the equivalent elements of the claims are included in the present application. Any figure mark in the claims should not be regarded as limiting the claims involved. In addition, the terms used in the embodiments of the present application are for the purpose of describing specific embodiments only and are not intended to limit the present invention.

[0079] It should be noted that the terms "first", "second", etc. in the specification and claims of this application and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the invention described herein can be implemented in an order other than those illustrated or described herein. The singular forms "a", "said", and "the" used in the embodiments of this application are also intended to include the plural forms, unless the context clearly indicates otherwise. In addition, the terms "comprises," "comprising," and "having," and any variations thereof, are intended to cover non-exclusive inclusions. For example, a process, method, system, product, or apparatus that includes a series of steps or elements is not necessarily limited to those steps or elements explicitly listed, but may include other steps or elements not explicitly listed or inherent to such process, method, product, or apparatus.

[0080] In the description of this application, unless otherwise specified, " / " indicates that the objects associated before and after are in an "or" relationship, for example, A / B can represent A or B; "and / or" in this application is only a description of the association relationship of the associated objects, indicating that there can be three relationships, for example, A and / or B, in the description of this application, unless otherwise specified, " / " indicates that the objects associated before and after are in an "or" relationship, for example, A / B can represent A or B; "and / or" in this application is only a description of the association relationship of the associated objects, indicating that there can be three relationships, for example, A and / or B, which can represent: A exists alone, A and B exist at the same time, and B exists alone, where A and B can be singular or plural. Depending on the context, the words "if" or "if" as used herein can be interpreted as "at..." or "when..." or "in response to determination" or "in response to detection". Similarly, the phrases “if determined” or “if (stated condition or event) is detected” may be interpreted as “when determined” or “in response to determining” or “when (stated condition or event) is detected” or “in response to detecting (stated condition or event)”, depending on the context.

[0081] The above embodiments are only used to illustrate the technical solutions of the present application, rather than to limit them. Although the present application has been described in detail with reference to the aforementioned embodiments, a person of ordinary skill in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features thereof may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the scope of the technical solutions of the embodiments of the present application.

Claims

1. A microneedle patch, characterized in that: The microneedle patch is a multi-layer structure, which is laminated from top to bottom and includes: a patch base film, a micro-control layer, an intermediate connection layer and a microneedle array layer; The microneedle array layer includes a plurality of microneedles, each of which is a hollow structure extending from the bottom end of the needle body to the tip end of the needle body; The hollow structure is provided with a thermal phase change material mixed with medicine; An electric heating layer is arranged on the inner wall of the hollow structure and the bottom end of the needle body, the electric heating layer covers the thermal phase change material and leaves a gap for releasing the drug near the tip of the needle body; A resistance detection layer extending to the bottom end of the needle body is arranged on the outer wall of the hollow structure, and the resistance detection layer is coupled to the interleukin receptor IL-17RA; The intermediate connection layer includes a plurality of first connection circuits and a plurality of second connection circuits; each of the first connection circuits is electrically connected to the resistance detection layer of at least one microneedle, each of the second connection circuits is electrically connected to the electric heating layer of at least one microneedle, and the first circuits and the second circuits are respectively connected to the micro-control layer; The micro-control layer detects the resistance change of the resistance detection layer on the corresponding microneedle based on the first connection circuit, and controls the heating of the electric heating layer of at least one microneedle based on the resistance change and the second connection circuit.

2. The microneedle patch according to claim 1, characterized in that The drug is composed of bimegetinib, and the thermal phase-change conductive material undergoes a solid-liquid phase change when heated, so that liquid drug molecules flow out from the bottom of the needle body and act on the conjunctiva.

3. The microneedle patch according to claim 1, characterized in that: The microneedle array layer is divided into multiple areas, and the resistance detection layers of multiple microneedles in each area are connected in series and electrically connected to an independent first connection circuit; the electric heating layers of multiple microneedles in each area are connected in series and electrically connected to an independent second connection circuit; when the resistance of any microneedle in the area increases, the micro-control layer electrically heats the electric heating layer of the microneedles in the area by electrically connecting the second connection circuit of the area.

4. The microneedle patch according to claim 1, characterized in that: The resistance detection layer of each microneedle in the microneedle array layer is electrically connected to an independent first connection circuit; the electric heating layer of each microneedle is electrically connected to an independent second connection circuit; when the resistance of any microneedle increases, the micro-control layer electrically heats the electric heating layer of the microneedle by electrically connecting the second connection circuit of the microneedle.

5. The microneedle patch according to claim 1, characterized in that: The resistance detection layer is a conductive path formed by a conductive layer coupled with the interleukin receptor IL-17RA, and the conductive path extends from the tip of the needle body to the bottom of the needle body and is electrically connected to the first connection circuit at the bottom of the needle body; When the inflammatory factor IL-17A interacts with IL-17RA, reactants are produced that increase the resistance of the conductive pathway and are recognized by the micro-control layer.

6. The microneedle patch according to claim 1, characterized in that: The electric heating layer extends from the needle tip to the needle bottom along the inner wall of the hollow structure.

7. The microneedle patch according to claim 1, characterized in that: The microneedle patch is of a configuration matching the shape of the conjunctiva of the eyelid, and the base membrane of the patch is made of a hydrophilic and breathable material; each of the microneedles is made of a conductive and insulating material.

8. The microneedle patch according to claim 1, characterized in that: The micro-control layer includes: a micro-control chip and a power supply, and the power supply is electrically connected to each first connection circuit and each second connection circuit through the micro-control chip.

9. The microneedle patch according to claim 1, characterized in that: The heating temperature of the electric heating layer of the microneedle is 38 to 42 degrees Celsius; The micro-control layer is activated once at a first predetermined time interval, and the heating temperature is determined according to the time to heat the entire electric heating layer to a predetermined temperature to control the release rate of the drug; The micro-control layer is activated once at a second predetermined time interval, and the heating temperature of the conductive heating wire in each microneedle is differentially set according to the difference between the resistance of each microneedle and the preset reference resistance to control the release rate of the drug molecules of the thermal phase change material.

10. A drug administration control method based on the microneedle patch according to any one of claims 1 to 9, characterized in that: The method comprises: The micro-control layer is activated at intervals of a first time length to heat the electric heating layer, and the heating temperature is determined based on preset time-temperature relationship information; The micro-control layer is activated at a first time interval to obtain resistance information of each microneedle of the microneedle array layer, and based on preset resistance-temperature relationship information, the electric heating layer in the microneedle is subjected to differential heating control; After the electric heating layer is heated, the thermal phase change material in contact with the electric heating layer undergoes a phase change, and the drug molecules flow out of the hollow microneedles and act on the conjunctiva.

Citation Information

Patent Citations

  • Hydrogel microneedle patch

    CN217548789U

  • Apparatus and methods for evaluating the barrier properties of a membrane

    US20070183936A1

  • Phase-transition polymeric microneedles

    US20110195124A1

  • Microneedle treatment system

    WO2019046333A1

Cited By

  • Microneedle patch device for delivering medicine

    CN119770844A

  • Muscle relaxing and massaging device for critical nursing

    CN120284690A